Clinical Trial Update: Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis [Phase 4]

View source ↗

Summary

A Phase 4 open-label study assessed intravenous zoledronic acid 4 mg for effects on bone density in hormone-sensitive metastatic prostate cancer patients with b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 4 | Status: COMPLETED